Q1 Earnings Forecast for XENE Issued By HC Wainwright

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – HC Wainwright issued their Q1 2026 EPS estimates for Xenon Pharmaceuticals in a report issued on Friday, February 28th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings per share of ($1.32) for the quarter. HC Wainwright has a “Buy” rating and a $53.00 price target on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q2 2026 earnings at ($1.27) EPS, Q3 2026 earnings at ($1.30) EPS and Q4 2026 earnings at ($1.42) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.05.

XENE has been the subject of several other reports. William Blair reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday. Deutsche Bank Aktiengesellschaft initiated coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Xenon Pharmaceuticals presently has an average rating of “Buy” and an average target price of $57.38.

Xenon Pharmaceuticals Trading Down 3.4 %

Shares of XENE stock opened at $37.02 on Monday. The stock has a market cap of $2.82 billion, a P/E ratio of -13.13 and a beta of 1.20. Xenon Pharmaceuticals has a 1 year low of $33.27 and a 1 year high of $50.99. The stock has a 50 day simple moving average of $39.27 and a 200 day simple moving average of $40.33.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC increased its position in Xenon Pharmaceuticals by 144.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock worth $100,506,000 after purchasing an additional 1,507,135 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Xenon Pharmaceuticals by 1,263.2% during the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock worth $38,456,000 after buying an additional 905,129 shares during the last quarter. FMR LLC increased its holdings in shares of Xenon Pharmaceuticals by 8.8% during the fourth quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company’s stock worth $294,991,000 after buying an additional 607,606 shares in the last quarter. Boxer Capital Management LLC acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth $23,520,000. Finally, Stempoint Capital LP bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at $14,733,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $40.20, for a total value of $903,213.60. Following the transaction, the chief executive officer now owns 31,302 shares in the company, valued at $1,258,340.40. The trade was a 41.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. In the last quarter, insiders have sold 57,492 shares of company stock valued at $2,334,969. 5.52% of the stock is currently owned by corporate insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.